I thought it was a solid report all around.
1. Revenue increasing and seems to be gaining traction. Further a tiny company with the ability to steal quite significant market share in the drug store sector is pretty impressive.
2. Agree that product is low price so will need volume. However with additional 2 product in market that should help.
3. Seems like they are hinting that an update on Rhinocan is imminent. so that should be a good catalyst. Again, they are a platform. I think that is overlooked by many.
4. yes I think a CR would be required and would be good for the company to grow at a faster rate.
